Search results for "Paclitaxel"

showing 7 items of 127 documents

Pegylated liposomal doxorubicin (PLD) and weekly paclitaxel (P) as second line chemotherapy in metastatic bladder cancer.

2008

bladder cancer Pegylated liposomal doxorubicin (PLD)weekly paclitaxel
researchProduct

Plasticizer extraction of Taxol infusion solution from various infusion devices.

1996

Taxol solution extracts the plasticizer DEHP (di(2-ethylhexyl)phthalate) from polyvinyl chloride (PVC) materials. In order to minimize patient exposure to DEHP, Taxol solutions should be prepared and administered in PVC-free materials. Particulate matter may form in Taxol infusion solution over time, so that in-line filtration with microporous membranes not greater than 0.22 microns is advisable. The purpose of this study was to evaluate the suitability of various administration- and in-line filter-sets for Taxol application. The extent of leached DEHP was determined using a Reversed Phase HPLC assay specific for DEHP. The four tested administration-sets, labeled as PVC-free, were all found…

endocrine systemPaclitaxelDrug StoragePharmaceutical Sciencemacromolecular substancesPharmacyToxicologylaw.inventionchemistry.chemical_compoundlawPlasticizersMicroporous membranesDiethylhexyl PhthalateHumansPharmacology (medical)Infusions IntravenousFiltrationChromatography High Pressure LiquidDrug PackagingPharmacologyChromatographyInfusion solutionorganic chemicalsExtraction (chemistry)PhthalatePlasticizerGeneral MedicineReversed-phase chromatographyAntineoplastic Agents PhytogenicPolyvinyl chloridechemistryPharmacy worldscience : PWS
researchProduct

Is G8 geriatric assessment tool useful in managing elderly patients with metastatic pancreatic carcinoma?

2020

Abstract Aim This paper aims to analyze the usefulness of the G8 geriatric oncology questionnaire in patients with advanced/metastatic pancreatic adenocarcinoma (aPAC) and its possible association with different clinical outcomes. Methods Patients age > 70 years were screened with the G8 tool and treated with intravenous nab-paclitaxel 125 mg/m2 and gemcitabine 1000 mg/m2 for 3 consecutive weeks followed by one-week rest as prescribed after clinical evaluation by treating oncologists. Patient’s charts were evaluated for type and severity of toxicity, 2 cycle rate of completion, discontinuation rate, delays, dose reductions, and other outcomes response rates, progression-free, and overall su…

medicine.medical_specialtyAdenocarcinoma03 medical and health sciences0302 clinical medicineInternal medicinePancreatic cancerAntineoplastic Combined Chemotherapy ProtocolsmedicineHumans030212 general & internal medicineGeriatric AssessmentAgedResponse rate (survey)business.industryGeriatric assessmentGemcitabine Maintenance Nab-paclitaxel Older adults Pancreatic cancerMetastatic Pancreatic Adenocarcinomamedicine.diseaseGemcitabineDiscontinuationPancreatic NeoplasmsOncologyGeriatric oncology030220 oncology & carcinogenesisToxicityGeriatrics and Gerontologybusinessmedicine.drug
researchProduct

Drug eluting and bare metal stents in people with and without diabetes: Collaborative network meta-analysis

2008

Objective To compare the effectiveness and safety of three types of stents (sirolimus eluting, paclitaxel eluting, and bare metal) in people with and without diabetes mellitus. Design Collaborative network meta-analysis. Data sources Electronic databases (Medline, Embase, the Cochrane Central Register of Controlled Trials), relevant websites, reference lists, conference abstracts, reviews, book chapters, and proceedings of advisory panels for the US Food and Drug Administration. Manufacturers and trialists provided additional data. Review methods Network meta-analysis with a mixed treatment comparison method to combine direct within trial comparisons between stents with indirect evidence fr…

medicine.medical_specialtyPaclitaxelmedicine.medical_treatment030204 cardiovascular system & hematologyCoronary Restenosis03 medical and health scienceschemistry.chemical_compound0302 clinical medicineBlood vessel prosthesisInternal medicinemedicineHumans030212 general & internal medicinecardiovascular diseasesGeneral Environmental ScienceRandomized Controlled Trials as TopicSirolimusbusiness.industryResearchHazard ratioGeneral EngineeringDrug-Eluting StentsGeneral Medicineequipment and supplies3. Good healthSurgeryBlood Vessel ProsthesisProsthesis FailureClinical trialsurgical procedures operativePaclitaxelchemistryDrug-eluting stentMeta-analysisSirolimusGeneral Earth and Planetary SciencesPlatelet aggregation inhibitorStentsbusinessDiabetic AngiopathiesPlatelet Aggregation Inhibitorsmedicine.drug
researchProduct

Estudio del efecto del paclitaxel en las propiedades físicas, biomecánicas y fisiológicas del tejido cutáneo en pacientes oncológicos y en cultivos d…

2020

La toxicidad en la piel es uno de los efectos perjudiciales más comunes de los taxanos. El objetivo fue evaluar el efecto del fármaco paclitaxel sobre la piel en un grupo de pacientes con cáncer ginecológico, y en un modelo 3D in vitro de piel, así como en melanocitos, queratinocitos, fibroblastos y en células microvasculares dérmicas humanas. En el estudio in vivo se realizaron las medidas en una población control de mujeres sanas (n=20) y una población de pacientes con tumores ginecológicos en tratamiento con paclitaxel (n=20), antes, durante y después. Las diferentes determinaciones fueron el valor de hidratación, la TEWL, el valor de sebo, valores de pigmentación y eritema, valores de e…

paclitaxeltoxicidad cutáneaUNESCO::CIENCIAS MÉDICAS ::Ciencias clínicas::Oncología:CIENCIAS MÉDICAS ::Ciencias clínicas::Dermatología [UNESCO]modelo piel 3DUNESCO::CIENCIAS MÉDICAS ::Ciencias clínicas::Dermatología:CIENCIAS MÉDICAS ::Farmacología [UNESCO]:CIENCIAS MÉDICAS ::Farmacodinámica::Quimioterapia [UNESCO]:CIENCIAS MÉDICAS ::Ciencias clínicas::Oncología [UNESCO]tumores ginecológicosUNESCO::CIENCIAS MÉDICAS ::Farmacodinámica::QuimioterapiaUNESCO::CIENCIAS MÉDICAS ::Farmacología
researchProduct

Estudio farmacogenético del tratamiento del cáncer de mama basado en antraciclinas y taxanos

2016

Existe una importante variabilidad interindividual en la respuesta a los medicamentos que condiciona que no sea fácil predecir la efectividad o seguridad de un fármaco en un paciente concreto. La Farmacogenética (PGt) estudia el vínculo entre las variaciones en la secuencia de ADN de un paciente y su respuesta al tratamiento farmacológico. La variación de un único nucleótido puede tener consecuencias dramáticas, de modo que la identificación de variantes que alteren la función o expresión de las proteínas implicadas en la farmacocinética o farmacodinamia y su efecto final sobre la respuesta es el objetivo de la PGt. El Cáncer de Mama (CM) es el tipo de cáncer más frecuente en mujeres. A pes…

taxanosantraciclinas:CIENCIAS DE LA VIDA::Genética [UNESCO]doxorubicina:CIENCIAS MÉDICAS ::Farmacología [UNESCO]SNPreacción adversa:CIENCIAS MÉDICAS ::Ciencias clínicas::Oncología [UNESCO]UNESCO::CIENCIAS MÉDICAS ::Farmacodinámica::QuimioterapiapolimorfismoepirubicinaUNESCO::CIENCIAS MÉDICAS ::FarmacologíafarmacogenéticapaclitaxelUNESCO::CIENCIAS MÉDICAS ::Ciencias clínicas::OncologíaUNESCO::CIENCIAS DE LA VIDA::Genéticacáncermama:CIENCIAS MÉDICAS ::Farmacodinámica::Quimioterapia [UNESCO]docetaxeltoxicidadantineoplásicoquimioterapia
researchProduct

Impressive objective response to nab-paclitaxel plus trastuzumab as fifth line therapy in aelderly her2-positive breast cancer patient

2020

Agent targeting HER-2 pathway plus chemotherapy has represented a major progress in the management of patients with breast cancer. However the role of late-line treatment in heavily pretreated patients is largely unclear. In the last decade nab-paclitaxel has show significant activity and good toxicity profile in metastatic breast cancer. We report the case of a 76-year-old Caucasian woman with metastatic HER-2 positive ductal infiltrating breast carcinoma treated with a combination of weekly nab-paclitaxel and trastuzumab as fifth-line therapy. She had previously received first-line paclitaxel and trastuzumab, second-line vinorelbine and trastuzumab, third-line TDM1 and fourth-line oral ca…

trastuzumabbreast cancerHER-2metastasisNab-paclitaxel
researchProduct